Premium
Adjunctive therapies in Kawasaki disease
Author(s) -
Tremoulet Adriana H.
Publication year - 2018
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.13208
Subject(s) - kawasaki disease , medicine , adjunctive treatment , coronary artery aneurysm , coronary artery disease , artery , antibody , disease , cardiology , immunology
Despite the administration of intravenous immunoglobulin ( IVI g) at a dose of 2 g/kg, approximately 3–5% of children with acute Kawasaki disease ( KD ) may develop coronary artery aneurysms. IVI g‐resistance, defined as recrudescence of fever more than 36 h after IVI g completion, is a risk factor for coronary artery abnormalities. Thus, several adjunctive therapies are being evaluated for use in IVI g‐resistant KD patients and in patients with coronary artery abnormalities. In this review the role of some of these adjunctive therapies in treatment of children with KD is discussed.